Skip to playerSkip to main content
  • 20 minutes ago
Scientists at the University of Texas at Austin have introduced an innovative experimental compound aimed at targeting cancer cells via dual metabolic pathways. This drug enhances glucose breakdown while concurrently inhibiting fatty-acid metabolism, leading to significant metabolic strain on cancer cells. In studies conducted on mice with aggressive melanoma, the treatment successfully eradicated the majority of cancer cells while exerting minimal impact on healthy cells. Additionally, laboratory assessments indicated efficacy against melanoma, leukemia, as well as breast, lung, liver, and neuroblastoma cancers. These discoveries are in preliminary stages, necessitating comprehensive testing prior to the commencement of human trials.

Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools.
ai-generated
Transcript
00:00Researchers in Texas may have found a new way to attack cancer.
00:03Scientists at the University of Texas at Austin
00:06developed an experimental compound called XJ485.
00:11The drug targets cancer's unusual dependence on sugar for energy.
00:15But it doesn't simply starve cancer cells.
00:18Instead, it pushes sugar metabolism into overdrive.
00:21At the same time, it blocks the cells from using fat as another energy source.
00:26That creates extreme metabolic stress inside cancer cells.
00:30In tests on mice with aggressive melanoma, the treatment killed most cancer cells.
00:35Researchers also found activity against several human cancer cell types.
00:40These included melanoma, leukemia, breast, lung, liver, and neuroblastoma cancers.
00:46The approach could offer a smaller chemical alternative to some antibody-based treatments.
00:51But researchers stress this is still early-stage work.
00:54The compound has not yet been tested in people.
00:58Much more research is needed before human trials can begin.
01:02Disclosure.
01:02This video contains stock footage and content created or enhanced using AI-assisted tools.
01:07The
01:07Disclosure.
01:07Disclosure.
Comments

Recommended